In vitro activity of fosfomycin against mucoid and non-mucoid Pseudomonas aeruginosa strains
Objectives: Pseudomonas aeruginosa is the most frequent infectious agent in cystic fibrosis patients. P. aeruginosa resistance to first line antibiotics limits therapeutic options, but the therapeutic potential of older generation antibiotics, such as fosfomycin is under investigation. Fosfomycin do...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2020-03-01
|
| Series: | Journal of Global Antimicrobial Resistance |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2213716520300436 |
| _version_ | 1831557624328355840 |
|---|---|
| author | A Bressan DM Rodio F Stangherlin G Puggioni C Ambrosi G Arcari A Carattoli G Antonelli V Pietropaolo M Trancassini |
| author_facet | A Bressan DM Rodio F Stangherlin G Puggioni C Ambrosi G Arcari A Carattoli G Antonelli V Pietropaolo M Trancassini |
| author_sort | A Bressan |
| collection | DOAJ |
| description | Objectives: Pseudomonas aeruginosa is the most frequent infectious agent in cystic fibrosis patients. P. aeruginosa resistance to first line antibiotics limits therapeutic options, but the therapeutic potential of older generation antibiotics, such as fosfomycin is under investigation. Fosfomycin does not belong to any other antibiotic class and acts by inhibiting the biosynthesis of the bacterial cell wall during the initial phases. A major problem for the use of fosfomycin against P. aeruginosa is the absence of a clinical breakpoint, the last one of 32 μg/mL was proposed in 2013 by the CA-SFM (Comité de l’Antibiogramme de la Société Française de Microbiologie). Methods: Sixty-one strains of P. aeruginosa (thirty mucoid and thirty-one non mucoid) were collected from respiratory samples of cystic fibrosis patients. All isolates were identified by MALDI-TOF (Bruker, Bremen, Germany). Fosfomycin MICs against P. aeruginosa were measured using an automated system and confirmed by the gold standard method. Results: There was no significant difference between mucoid and non-mucoid strains. MIC distribution and susceptibility rates were obtained by agar dilution method and from this data we measured MIC50 and MIC90 which were equal to 32 μg/mL and 64 μg/mL, respectively. From automated method results we measured a very major error (VME), major error (ME) and categorical agreement (CA) which were equal to 0%, 11% and 89%, respectively. Comparing automated and agar dilution methods, a Cohen’s kappa equal to 73% (0.726) was measured. Conclusions: Our data suggest that fosfomycin has good effect against mucoid and non-mucoid strains of P. aeruginosa and automated systems can be implemented in clinical microbiology laboratories to assess fosfomycin with rapid and reproducible results. |
| first_indexed | 2024-12-17T04:55:16Z |
| format | Article |
| id | doaj.art-1e8ca99b1f784958b835c7f5097d572e |
| institution | Directory Open Access Journal |
| issn | 2213-7165 |
| language | English |
| last_indexed | 2024-12-17T04:55:16Z |
| publishDate | 2020-03-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Journal of Global Antimicrobial Resistance |
| spelling | doaj.art-1e8ca99b1f784958b835c7f5097d572e2022-12-21T22:02:44ZengElsevierJournal of Global Antimicrobial Resistance2213-71652020-03-0120328331In vitro activity of fosfomycin against mucoid and non-mucoid Pseudomonas aeruginosa strainsA Bressan0DM Rodio1F Stangherlin2G Puggioni3C Ambrosi4G Arcari5A Carattoli6G Antonelli7V Pietropaolo8M Trancassini9Department of Molecular Medicine, ''Sapienza'' University Rome, Rome, ItalyDepartment of Public Health and Infectious Diseases, ''Sapienza'' University Rome, ItalyDepartment of Clinical Medicine, ''Sapienza'' University Rome, Rome, ItalyDepartment of Molecular Medicine, ''Sapienza'' University Rome, Rome, ItalyDepartment of Public Health and Infectious Diseases, ''Sapienza'' University Rome, ItalyDepartment of Molecular Medicine, ''Sapienza'' University Rome, Rome, ItalyDepartment of Molecular Medicine, ''Sapienza'' University Rome, Rome, ItalyDepartment of Molecular Medicine, ''Sapienza'' University Rome, Rome, ItalyDepartment of Public Health and Infectious Diseases, ''Sapienza'' University Rome, ItalyDepartment of Public Health and Infectious Diseases, ''Sapienza'' University Rome, Italy; Corresponding author at: Department of Public Health and Infectious Diseases, ''Sapienza'' University Rome, P.le Aldo Moro, 5, 00185, Rome, Italy.Objectives: Pseudomonas aeruginosa is the most frequent infectious agent in cystic fibrosis patients. P. aeruginosa resistance to first line antibiotics limits therapeutic options, but the therapeutic potential of older generation antibiotics, such as fosfomycin is under investigation. Fosfomycin does not belong to any other antibiotic class and acts by inhibiting the biosynthesis of the bacterial cell wall during the initial phases. A major problem for the use of fosfomycin against P. aeruginosa is the absence of a clinical breakpoint, the last one of 32 μg/mL was proposed in 2013 by the CA-SFM (Comité de l’Antibiogramme de la Société Française de Microbiologie). Methods: Sixty-one strains of P. aeruginosa (thirty mucoid and thirty-one non mucoid) were collected from respiratory samples of cystic fibrosis patients. All isolates were identified by MALDI-TOF (Bruker, Bremen, Germany). Fosfomycin MICs against P. aeruginosa were measured using an automated system and confirmed by the gold standard method. Results: There was no significant difference between mucoid and non-mucoid strains. MIC distribution and susceptibility rates were obtained by agar dilution method and from this data we measured MIC50 and MIC90 which were equal to 32 μg/mL and 64 μg/mL, respectively. From automated method results we measured a very major error (VME), major error (ME) and categorical agreement (CA) which were equal to 0%, 11% and 89%, respectively. Comparing automated and agar dilution methods, a Cohen’s kappa equal to 73% (0.726) was measured. Conclusions: Our data suggest that fosfomycin has good effect against mucoid and non-mucoid strains of P. aeruginosa and automated systems can be implemented in clinical microbiology laboratories to assess fosfomycin with rapid and reproducible results.http://www.sciencedirect.com/science/article/pii/S2213716520300436FosfomycinMucoid Pseudomonas aeruginosaAgar dilutionAutomated system |
| spellingShingle | A Bressan DM Rodio F Stangherlin G Puggioni C Ambrosi G Arcari A Carattoli G Antonelli V Pietropaolo M Trancassini In vitro activity of fosfomycin against mucoid and non-mucoid Pseudomonas aeruginosa strains Journal of Global Antimicrobial Resistance Fosfomycin Mucoid Pseudomonas aeruginosa Agar dilution Automated system |
| title | In vitro activity of fosfomycin against mucoid and non-mucoid Pseudomonas aeruginosa strains |
| title_full | In vitro activity of fosfomycin against mucoid and non-mucoid Pseudomonas aeruginosa strains |
| title_fullStr | In vitro activity of fosfomycin against mucoid and non-mucoid Pseudomonas aeruginosa strains |
| title_full_unstemmed | In vitro activity of fosfomycin against mucoid and non-mucoid Pseudomonas aeruginosa strains |
| title_short | In vitro activity of fosfomycin against mucoid and non-mucoid Pseudomonas aeruginosa strains |
| title_sort | in vitro activity of fosfomycin against mucoid and non mucoid pseudomonas aeruginosa strains |
| topic | Fosfomycin Mucoid Pseudomonas aeruginosa Agar dilution Automated system |
| url | http://www.sciencedirect.com/science/article/pii/S2213716520300436 |
| work_keys_str_mv | AT abressan invitroactivityoffosfomycinagainstmucoidandnonmucoidpseudomonasaeruginosastrains AT dmrodio invitroactivityoffosfomycinagainstmucoidandnonmucoidpseudomonasaeruginosastrains AT fstangherlin invitroactivityoffosfomycinagainstmucoidandnonmucoidpseudomonasaeruginosastrains AT gpuggioni invitroactivityoffosfomycinagainstmucoidandnonmucoidpseudomonasaeruginosastrains AT cambrosi invitroactivityoffosfomycinagainstmucoidandnonmucoidpseudomonasaeruginosastrains AT garcari invitroactivityoffosfomycinagainstmucoidandnonmucoidpseudomonasaeruginosastrains AT acarattoli invitroactivityoffosfomycinagainstmucoidandnonmucoidpseudomonasaeruginosastrains AT gantonelli invitroactivityoffosfomycinagainstmucoidandnonmucoidpseudomonasaeruginosastrains AT vpietropaolo invitroactivityoffosfomycinagainstmucoidandnonmucoidpseudomonasaeruginosastrains AT mtrancassini invitroactivityoffosfomycinagainstmucoidandnonmucoidpseudomonasaeruginosastrains |